Lukas Leow

Lukas Leow is a fund manager at Bellevue Asset Management, a Swiss investment firm that specializes in healthcare investments. He has been actively involved in discussions related to the pharmaceutical market, particularly regarding the performance and forecasts of companies like Novo Nordisk, in which he holds shares. Recently, he commented on the company's sales growth expectations for its obesity drug Wegovy.